Keyword Analysis & Research: neurona therapeutics
Keyword Research: People who searched neurona therapeutics also searched
Search Results related to neurona therapeutics on Search Engine
-
Neurona Therapeutics | NRTX-1001 Inhibitory Neuron Cell Therapy
https://www.neuronatherapeutics.com/
WEBA wholly-owned pipeline of novel cell therapy products. Neurona is developing allogeneic, off-the-shelf neural cell therapies for multiple chronic neurological disorders. The pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, a first-in-class inhibitory neuron therapy for epilepsy.
DA: 76 PA: 45 MOZ Rank: 67
-
Mission | Leadership | Investors | Neurona Therapeutics
https://www.neuronatherapeutics.com/about/
WEBNeurona Therapeutics is a privately-held, clinical-stage biotherapeutics company focused on discovering and developing allogeneic neural cell therapies to treat chronic diseases of the nervous system. Neurona was founded by leading-edge neuroscientists and stem cell pioneers at the University of California, San Francisco.
DA: 53 PA: 44 MOZ Rank: 69
-
Regenerative Pluripotent Stem Cell Technology | Neurona Therapeutics
https://www.neuronatherapeutics.com/technology/
WEBNeurona is developing off-the-shelf, allogeneic neuronal, glial, and gene-edited neural cell therapies for single-dose targeted repair of the nervous system. Neurona’s discovery platform is powered by regenerative pluripotent stem cell technology and used to develop proprietary manufacturing processes that produce authentic neural cell ...
DA: 81 PA: 3 MOZ Rank: 22
-
Neurona Therapeutics Presents Positive Clinical Update from …
https://www.neuronatherapeutics.com/news/press-releases/041524/
WEB4 days ago · Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting. – NRTX-1001 administration has been well-tolerated in all individuals treated to date. – 4 of 5 subjects treated with the lower dose of NRTX-1001 ...
DA: 26 PA: 55 MOZ Rank: 23
-
Brain-cell transplants are the newest experimental epilepsy treatment
https://www.technologyreview.com/2024/03/29/1090301/brain-cell-transplants-are-the-newest-experimental-epilepsy-treatment/
WEBMar 29, 2024 · The treatment, developed by Neurona Therapeutics, is shaping up as a breakthrough for stem-cell technology. That's the idea of using embryonic human cells, or cells converted to an...
DA: 63 PA: 39 MOZ Rank: 64
-
NRTX-1001 | Focal Epilepsies | Alzheimer’s | Neurona Therapeutics
https://www.neuronatherapeutics.com/pipeline/
WEBThe NRTX-1001 inhibitory neurons are targeted to the seizure-onset zone to enhance GABAergic inhibition, reduce seizure activity, and repair the affected neural network. NRTX-1001 is delivered as a single, one-time dose and is intended to persist and provide long-term seizure suppression.
DA: 59 PA: 93 MOZ Rank: 62
-
Neurona Therapeutics Raises $120M to Advance Groundbreaking …
https://www.neuronatherapeutics.com/news/press-releases/020824/
WEBSan Francisco, CA, February 8, 2024 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the successful completion of a $120 million financing co-led by Viking Global Investors and Cormorant Asset Management with ...
DA: 88 PA: 22 MOZ Rank: 5
-
Neurona Therapeutics Announces Initial Subject Dosed in First …
https://www.neuronatherapeutics.com/news/press-releases/062922/
WEBSan Francisco, CA, June 29, 2022 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epilepsy study.
DA: 91 PA: 12 MOZ Rank: 59
-
Neurona Therapeutics Raises $120M to Advance Groundbreaking …
https://finance.yahoo.com/news/neurona-therapeutics-raises-120m-advance-130000173.html
WEBSAN FRANCISCO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...
DA: 36 PA: 14 MOZ Rank: 9
-
Neurona Therapeutics Announces FDA Clearance of Expanded
https://www.globenewswire.com/news-release/2023/02/14/2607560/0/en/Neurona-Therapeutics-Announces-FDA-Clearance-of-Expanded-Inclusion-Criteria-for-Phase-I-II-Clinical-Trial-of-NRTX-1001-Regenerative-Cell-Therapy-in-Patients-with-Dominant-Hemispher.html
WEBSAN FRANCISCO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological...
DA: 18 PA: 95 MOZ Rank: 31
